RFL - Rafael Holdings, Inc.
After hours:
Chart Events
Short-term KST
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 2.2700 |
| Open | 2.2700 |
| Bid | 2.0600 x 1800 |
| Ask | 2.5000 x 1800 |
| Day's Range | 2.2600 - 2.3100 |
| 52 Week Range | 1.5500 - 2.7400 |
| Volume | |
| Avg. Volume | 62,293 |
| Market Cap | 55.914M |
| Beta (5Y Monthly) | 1.66 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8100 |
| Earnings Date | Jun 12, 2023 - Jun 16, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- Business Wire
Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement
GAINESVILLE, Fla., June 05, 2023--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has entered into a binding agreement with Rafael Holdings, Inc. (NYSE:RFL) ("Rafael") under which Rafael has agreed to purchase 4,000,000 shares of common stock of Cyclo Therapeutics and warrants
- Business Wire
Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
GAINESVILLE, Fla., May 15, 2023--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the first quarter of 2023 and provided a business update.
- Business Wire
Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)
GAINESVILLE, Fla., May 02, 2023--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has closed a private placement of its securities with Rafael Holdings, Inc. (NYSE:RFL) ("Rafael") for the purchase of 2,514,970 shares of common stock and warrants to purchase an additional 2,514,
GlobeNewswireRafael Holdings Announces up to $5 Million Share Repurchase Program
Announces expanded search for strategic opportunities beyond biopharmaNEWARK, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today announced that its Board of Directors has authorized the repurchase of up to $5 million of the Company's Class B common stock. “We remain committed to strategically and opportunistically deploying capital to drive long-term stockholder value. In the current macroeconomic environment, given the strength of our balance sheet and our share p
- GlobeNewswire
Rafael Holdings Reports Second Quarter Fiscal 2023 Financial Results
NEWARK, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its second quarter fiscal 2023 financial results for the three months and six months ended January 31, 2023. “Our strong balance sheet allows us to continue to fund our pipeline assets and explore selective strategic business development opportunities, which potentially could improve the lives of patients and generate value for our shareholders,” said Bill Conkling, CEO of Rafael Holdings. Rafael H
- GlobeNewswire
Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results
NEWARK, N.J., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its first quarter fiscal 2023 financial results for the three months ended October 31, 2022. “We are pleased to have successfully completed the sale of our real estate asset located in Newark NJ during the first quarter of fiscal 2023, and believe that our strong balance sheet provides us the opportunity to focus on strategic business development efforts. Our goal is to acquire, in-license or invest
- GlobeNewswire
Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities
NEWARK, N.J., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today announced its decision to curtail its early-stage development efforts, including pre-clinical research at the Barer Institute in order to reduce spending and focus on exploring strategic opportunities to invest in, acquire, or in-license clinical stage assets. As of July 31, 2022, the Company held cash, cash equivalents and marketable securities of $63.2 million, and subsequently received $33 million in net p
- GlobeNewswire
Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results
NEWARK, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), a holding company with interests in clinical and early-stage pharmaceutical companies, today reported its financial results for the three and twelve months ended July 31, 2022. The Company is accelerating its focus on exploring strategic opportunities to further enhance value while continuing to develop and evaluate its pipeline. “With the net proceeds of $33 million received in August 2022 from the sale of real e
GlobeNewswireCornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer
Clinical program advancement represents key milestone for Cornerstone underscoring its commitment to the development of lead compound, devimistat, in pancreatic cancerCranbury, Sept. 28, 2022 (GLOBE NEWSWIRE) -- September 28, 2022 - Cornerstone Pharmaceuticals, Inc., a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the initiation of a Phase 1 clinical trial evaluating CPI-613® (devimistat) in combination with chemoradiation for the treat
- GlobeNewswire
Rafael Holdings Sells its Building Located at 520 Broad Street in Newark, New Jersey and Associated 800-Car Public Garage
NEWARK, N.J., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE: RFL), an early-stage novel cancer and immune metabolism therapeutics company, today announced that it has closed on the sale of the building housing its headquarters to affiliates of The Sinai Equity Group. The building located at 520 Broad Street in Newark, New Jersey and an associated 800-car public garage sold for a total purchase price of $49.4 million. Rafael Holdings expects net proceeds of approximately $33 mill
- GlobeNewswire
Cornerstone Pharmaceuticals Announces Successful Completion of Phase 1b Clinical Trial for CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer
CRANBURY, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the successful completion of a Phase 1b clinical trial of CPI-613® (devimistat) in combination with gemcitabine and cisplatin for the treatment of advanced unresectable biliary tract cancer. In collaboration with Michigan Medicine, the Phase 1b study consisted of a multicen
Simply Wall St.Howard Jonas Is The Founder & Chairman of Rafael Holdings, Inc. (NYSE:RFL) And They Just Picked Up 83% More Shares
Those following along with Rafael Holdings, Inc. ( NYSE:RFL ) will no doubt be intrigued by the recent purchase of...
GlobeNewswireCornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.
CRANBURY, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the appointment of Jason Locasale, Ph.D., as a member of the Company’s Scientific Advisory Board. Dr. Locasale is a highly respected scholar and brings to Cornerstone deep expertise in cancer metabolism, metabolomics, nutrition and the metabolic interface of epigenetics. “D
- GlobeNewswire
Cornerstone Pharmaceuticals to Present Pancreatic Cancer Data on CPI-613® (Devimistat) From Its Open-Label Phase 1 Study at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022
CRANBURY, N.J., June 27, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced that data on its lead compound CPI-613® (devimistat) in combination with gemcitabine and nab-paclitaxel in patients with locally advanced or metastatic pancreatic cancer will be presented at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal
- GlobeNewswire
Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE
Cranbury, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced a publication on preclinical data supporting CPI-613® (devimistat) targeting carcinoma catabolism. The study published in PLOS ONE titled, “Evidence for a novel, effective approach to targeting carcinoma catabolism exploiting the first-in-class, anti-cancer mitochondrial dr
- GlobeNewswire
Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism
Cranbury, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced a publication on preclinical data supporting CPI-613® (devimistat) targeting carcinoma catabolism. The study published in PLOS ONE titled, “Evidence for a novel, effective approach to targeting carcinoma catabolism exploiting the first-in-class, anti-cancer mitochondrial dr
- GlobeNewswire
Rafael Holdings Reports Third Quarter Fiscal 2022 Financial Results
NEWARK, N.J., June 14, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), an early-stage novel cancer and immune metabolism therapeutics company, today reported its financial results for the three and nine months ended April 30, 2022. The Company is focused on accelerating the development of its novel cancer and immune metabolism pipeline while exploring strategic opportunities to further enhance value. “We are excited by the continuing progress our internal research and development tea